Skip to content

A randomized controlled study of Traditional Chinese Medicine Granules(Supplementing qi, activating blood and detoxifying method) combined with metronomic chemotherapy in the treatment of elderly patients with advanced breast cancer

A randomized controlled study of Traditional Chinese Medicine Granules(Supplementing qi, activating blood and detoxifying method) combined with metronomic chemotherapy in the treatment of elderly patients with advanced breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072272
Enrollment
Unknown
Registered
2023-06-08
Start date
2023-06-10
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

therapy group:Traditional Chinese Medicine Granules(Supplementing qi, activating blood and detoxifying method) combined with capecitabine metronomic chemotherapy
control group:Traditional Chinese medicine granule placebo combined with capecitabine metronomic chemotherapy

Sponsors

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: ?Age = 65 years old;? Clear pathological and molecular classification of breast cancer; ? Locally advanced unresectable or stage IV breast cancer with measurable lesions;?Hormone receptor-positive breast cancer or triple-negative breast cancer that failed CDK4/6 inhibitor therapy; ?KPS score = 60 points;?Bone marrow function and liver and kidney function up to standard (hemoglobin HB=90g/L, neutrophil count NC=1.5×109/L, platelet count PLT=90×109/L. Liver function is basically normal: ALT=2.5×ULN,AST=2.5×ULN, TBIL =1.5×ULN (ALT=5×ULN, AST=5×ULN, TBIL=3×ULN in patients with liver metastases);?Conform to clinical syndrome differentiation of Qi deficiency and blood stasis syndrome; ?Volunteer to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: ? HER2-positive breast cancer, ? patients with heavy tumor burden and rapid tumor progression determined by clinicians to be combined with chemotherapy for rapid relief of symptoms; ? patients with visceral crisis; ? patients who refused to take oral chemotherapy drugs;? Those who cannot cooperate with the evaluation and inspection of the test specifications; ? Those who cannot cooperate with the scale and symptoms for evaluation; ?Those who are allergic to the study drug.

Design outcomes

Primary

MeasureTime frame
clinical benefit rate;

Secondary

MeasureTime frame
Progression Free Survival Time;Quality of Life;

Countries

China

Contacts

Public ContactXue Na

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Dongcheng District, Beijing

me1988xuena@126.com+86 136 0122 9467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026